DBC1 re-expression alters the expression of multiple components of the plasminogen pathway

被引:16
作者
Louhelainen, JP [1 ]
Hurst, CD [1 ]
Pitt, E [1 ]
Nishiyama, H [1 ]
Pickett, HA [1 ]
Knowles, MA [1 ]
机构
[1] St James Univ Hosp, Canc Res UK, Ctr Clin, Leeds LS9 7TF, W Yorkshire, England
基金
英国惠康基金;
关键词
DBC1; bladder cancer; tumour suppressor gene; expression microarray;
D O I
10.1038/sj.onc.1209228
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Deleted in bladder cancer 1 (DBC1) is a candidate gene for the bladder tumour suppressor locus at 9q33.1. The function of the gene is currently unknown but a cross-species sequence comparison suggests an important role, as it is highly evolutionarily conserved. Here, we transfected a nonexpressing human bladder cancer cell line with a set of human DBC1 cDNA constructs. The effect on global expression patterns was assessed using cDNA microarrays. The cell clone with the lowest level of DBC1 expression showed induced expression of 26 genes including plasminogen activator inhibitor 2 (SERPINB5; 4.6-fold), heparin-binding EGF-like growth factor precursor ( DTR; 4.2-fold), small proline-rich protein 2B (SPRR2B; 3.6-fold), metallothionein 1 isoforms (MT1B/ MT1A/MT-1F; from 2.9- to 3.2-fold), tissue-type plasminogen activator precursor ( PLAT; 2.8-fold) and urokinasetype plasminogen activator precursor (PLAU; 2.7fold). In clustering analysis, both PLAT and PLAU clustered with the functionally related urokinase plasminogen activator surface receptor (PLAUR; 1.9-fold). Furthermore, 14 human bladder tumours were analysed by real-time quantitative PCR using gene-specific primers for selected (n = 20) genes. The expression levels of SERPINB5, PLAU, PLAUR and MT1 correlated with the DBC1 levels, suggesting previously unknown involvement of DBC1 in the urokinase-plasminogen pathway.
引用
收藏
页码:2409 / 2419
页数:11
相关论文
共 39 条
[1]  
BACHMANN F, 1995, THROMB HAEMOSTASIS, V74, P172
[2]   Identification of a candidate tumor-suppressor gene specifically activated during Ras-induced senescence [J].
Barradas, M ;
Gonos, ES ;
Zebedee, Z ;
Kolettas, E ;
Petropoulou, C ;
Delgado, MD ;
León, J ;
Hara, E ;
Serrano, M .
EXPERIMENTAL CELL RESEARCH, 2002, 273 (02) :127-137
[3]   Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma: diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis [J].
Champelovier, P ;
Boucard, N ;
Levacher, G ;
Simon, A ;
Seigneurin, D ;
Praloran, V .
UROLOGICAL RESEARCH, 2002, 30 (05) :301-309
[4]  
COHEN RL, 1989, J BIOL CHEM, V264, P8375
[5]  
ELLER MS, 1995, J CELL SCI, V108, P2741
[6]   RELATIONSHIP BETWEEN CATHEPSIN-D, UROKINASE, AND PLASMINOGEN-ACTIVATOR INHIBITORS IN MALIGNANT VS BENIGN BREAST-TUMORS [J].
FOUCRE, D ;
BOUCHET, C ;
HACENE, K ;
POURREAUSCHNEIDER, N ;
GENTILE, A ;
MARTIN, PM ;
DESPLACES, A ;
OGLOBINE, J .
BRITISH JOURNAL OF CANCER, 1991, 64 (05) :926-932
[7]   Definition of a 1-Mb homozygous deletion at 9q32-q33 in a human bladder-cancer cell line [J].
Fujiwara, H ;
Emi, M ;
Nagai, H ;
Ohgaki, K ;
Imoto, I ;
Akimoto, M ;
Ogawa, O ;
Habuchi, T .
JOURNAL OF HUMAN GENETICS, 2001, 46 (07) :372-377
[8]   Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion [J].
Fujiyama, C ;
Jones, A ;
Fuggle, S ;
Bicknell, R ;
Cranston, D ;
Harris, AL .
BRITISH JOURNAL OF CANCER, 2001, 84 (04) :558-564
[9]   Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32-q33 [J].
Habuchi, T ;
Luscombe, N ;
Elder, PA ;
Knowles, MA .
GENOMICS, 1998, 48 (03) :277-288
[10]   A novel candidate tumour suppressor locus at 9q32-33 in bladder cancer: Localization of the candidate region within a single 840 kb YAC [J].
Habuchi, T ;
Yoshida, O ;
Knowles, MA .
HUMAN MOLECULAR GENETICS, 1997, 6 (06) :913-919